Related Experiment Video
Updated: Jan 28, 2026

Treating Surfaces with a Cold Atmospheric Pressure Plasma using the COST-Jet
Published on: November 2, 2020
The cost effectiveness of treating Burkitt lymphoma in Uganda
Avram E Denburg1, Nazeefah Laher1,2, Innocent Mutyaba3,4
1The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada.
Insights
Treating childhood Burkitt lymphoma (BL) in Uganda is highly cost-effective, averting disability-adjusted life-years (DALYs) at a low cost. This finding supports prioritizing childhood cancer treatment programs in low- and middle-income countries (LMICs).
Area of Science:
- Global Health Economics
- Pediatric Oncology
- Health Policy Research
Background:
- Childhood cancer treatment programs face political barriers in low- and middle-income countries (LMICs) due to perceived high costs.
- Limited data exists on the actual cost and cost-effectiveness of these essential programs.
- Burkitt lymphoma (BL) is the most common childhood cancer in Africa, necessitating effective treatment strategies.
Purpose of the Study:
- To conduct an economic evaluation of a comprehensive BL treatment program in Uganda.
- To determine the cost-effectiveness of BL therapy in a low-income country (LIC) setting.
- To provide evidence for prioritizing childhood cancer treatment in LMICs.
Main Methods:
- A comparative analysis of BL treatment versus usual care for 122 patients (2012-2014).
- Inclusion of variable, fixed, and family costs in the economic evaluation.
- Calculation of cost per disability-adjusted life-year (DALY) averted using WHO-CHOICE methodology.
Main Results:
- The 2-year overall survival (OS) rate for treated patients was 55%.
- The cost per DALY averted was US$97 (Int$301), well within WHO-CHOICE thresholds.
- The intervention demonstrated a very cost-effective ratio of 0.14 to per capita GDP.
Conclusions:
- Locally tailored protocols for treating BL in LMICs are highly cost-effective by international standards.
- This study provides crucial evidence for policymakers regarding resource allocation for childhood cancers.
- Economic evaluations are vital for prioritizing noncommunicable disease interventions, including pediatric cancers, in LMICs.
Background:
Perceptions of high cost and resource intensity remain political barriers to the prioritization of childhood cancer treatment programs in many low- and middle-income countries (LMICs). Little knowledge exists of the actual cost and cost-effectiveness of such programs. To improve outcomes for children with Burkitt lymphoma (BL), the most common childhood cancer in Africa, the Uganda Cancer Institute implemented a comprehensive BL treatment program in 2012. We undertook an economic evaluation of the program to ascertain the cost-effectiveness of BL therapy in a specific LIC setting.
Methods:
We compared the treatment of BL to usual care in a cohort of 122 patients treated between 2012 and 2014. Costs included variable, fixed, and family costs. Our primary measure of effectiveness was overall survival (OS). Patient outcomes were determined through prospective capture and retrospective chart abstraction. The cost per disability-adjusted life-year (DALY) averted was calculated using the World Health Organization's Choosing Interventions That Are Cost-Effective (WHO-CHOICE) methodology.
Results:
The 2-year OS with treatment was 55% (95% CI, 45% to 64%). The cost per DALY averted in the treatment group was US$97 (Int$301). Cumulative estimate of national DALYs averted through treatment was 8607 years, and the total national annual cost of treatment was US$834,879 (Int$2,590,845). The cost of BL treatment fell well within WHO-CHOICE cost-effectiveness thresholds. The ratio of cost per DALY averted to per capita gross domestic product was 0.14, reflecting a very cost-effective intervention.
Conclusion:
This study demonstrates that treating BL with locally tailored protocols is very cost-effective by international standards. Studies of this kind will furnish crucial evidence to help policymakers prioritize the allocation of LMIC health system resources among noncommunicable diseases, including childhood cancer.
More Related Videos
07:12Bioluminescence-Based Tumor Quantification Method for Monitoring Tumor Progression and Treatment Effects in Mouse Lymphoma Models
Published on: July 7, 2016
07:52Multiplexed Fluorescent Immunohistochemical Staining, Imaging, and Analysis in Histological Samples of Lymphoma
Published on: January 9, 2019
Related Concept Videos
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Framing Effects
Biological Effects of Radiation
Effects of Creep
Extraction: Effects of pH
Solvating Effects